KEYPOINTS SpikoGen is a more traditional COVID-19 vaccine comprising SARS-CoV-2 spike protein extracellular domain formulated with Advax-CpG adjuvant SpikoGen differs from the Novavax vaccine in major ways including its use of the soluble secreted spike protein ECD rather than nanoparticle formulation and the use of a different adjuvant SpikoGen demonstrates robust protection against homologous and heterologous SARS-CoV-2 strains in hamster, ferret and non-human primate challenge models SpikoGen induces broadly cross-neutralizing antibodies, but still protects even after these antibody levels wane In a pivotal Phase 3 clinical trial, SpikoGen reduced the risk of severe infection by 77.5% and was not associated with myocarditis, thrombosis or any other adverse safety signals SpikoGen received an Emergency Use Authorization in the Middle East on 6 October 2021, making it the first recombinant spike protein vaccine to achieve this milestone Eight million doses of SpikoGen vaccine have been safely delivered to date Protein-based vaccines have a long history of reliability and safety
【저자키워드】 COVID-19, SARS-CoV-2, Vaccine, coronavirus, pandemic, adjuvant,